Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old | MicrobiomeTrials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-01Est. Completion: 2028-03
Enrollment target: 20 participants
Locations
Neurocrine Clinical Site, San Francisco, California, United States
Neurocrine Clinical Site, Hartford, Connecticut, United States
Neurocrine Clinical Site, Atlanta, Georgia, United States
Neurocrine Clinical Site, Chicago, Illinois, United States
Neurocrine Clinical Site, Indianapolis, Indiana, United States
Neurocrine Clinical Site, Ann Arbor, Michigan, United States
Neurocrine Clinical Site, Minneapolis, Minnesota, United States
Neurocrine Clinical Site, Philadelphia, Pennsylvania, United States
Neurocrine Clinical Site, Dallas, Texas, United States
Neurocrine Clinical Site, Seattle, Washington, United States